Oculis Holding AG (NASDAQ:OCS) Short Interest Down 21.0% in April

Oculis Holding AG (NASDAQ:OCS) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totalling 25,600 shares, a decrease of 21.0% from the March 31st total of 32,400 shares. Based on an average trading volume of 51,100 shares, the short-interest ratio is presently 0.5 days. Approximately 0.1% of the shares of the company are sold short.

Institutional Trading of Oculis

Several large investors have recently bought and sold shares of the company. Barclays PLC purchased a new stake in Oculis in the 2nd quarter valued at approximately $44,000. Wolverine Asset Management LLC purchased a new stake in shares of Oculis in the third quarter valued at $77,000. Compagnie Lombard Odier SCmA boosted its stake in shares of Oculis by 47.3% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company’s stock valued at $1,053,000 after acquiring an additional 30,750 shares during the last quarter. abrdn plc purchased a new stake in Oculis during the 4th quarter worth about $15,980,000. Finally, Searle & CO. acquired a new position in Oculis in the 4th quarter valued at about $112,000. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Stock Performance

Shares of NASDAQ OCS traded up $0.07 during midday trading on Friday, hitting $12.02. The company had a trading volume of 88,399 shares, compared to its average volume of 71,733. The company has a quick ratio of 5.29, a current ratio of 5.29 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $11.85 and a two-hundred day simple moving average of $11.24. Oculis has a twelve month low of $9.05 and a twelve month high of $14.50.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04. The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.28 million. Sell-side analysts predict that Oculis will post -1.72 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on OCS shares. HC Wainwright decreased their price target on Oculis from $29.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday. Chardan Capital restated a “buy” rating and issued a $30.00 target price on shares of Oculis in a research note on Tuesday, March 19th. Robert W. Baird dropped their price target on shares of Oculis from $64.00 to $35.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 19th. Finally, Wedbush restated an “outperform” rating and issued a $29.00 price objective on shares of Oculis in a research report on Wednesday, March 6th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $29.14.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.